<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-145905" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Laboratory Evaluation of Bone Marrow</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Swachi</given-names>
          </name>
          <aff>Hospital of University of Pennsylvania</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Rashi</given-names>
          </name>
          <aff>Medanta-The Medicity</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Swachi Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rashi Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-145905.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A thorough bone marrow evaluation is critical for diagnosing neoplastic and certain nonneoplastic hematopoietic conditions and monitoring patients undergoing bone marrow transplantation and chemotherapy. A comprehensive laboratory bone marrow examination includes a complete blood count (CBC) and analysis of the peripheral blood smear (PBS), bone marrow aspirate, core biopsy specimen, clot section, and cytometric flow. Integrating advanced diagnostic techniques, such as cytogenetics, fluorescence in situ hybridization (FISH), and molecular profiling in clinical practice is essential in diagnosing, classifying, and prognosticating bone marrow pathologies.<xref ref-type="bibr" rid="article-145905.r1">[1]</xref> Establishing uniform reporting systems and enhancing laboratory advancement awareness can promote efficient interprofessional collaboration and improve patient care quality.</p>
      </sec>
      <sec id="article-145905.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>Bone marrow examination is indicated in a range of clinical scenarios, including the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Unexplained cytosis, cytopenias, or atypical cells on PBS</p>
          </list-item>
          <list-item>
            <p>Diagnosing and staging of hematopoietic neoplasms</p>
          </list-item>
          <list-item>
            <p>Evaluation of radiologically detected osseous lesions concerning for metastases</p>
          </list-item>
          <list-item>
            <p>Investigating hepatosplenomegaly of unknown origin</p>
          </list-item>
          <list-item>
            <p>Pyrexia of unknown origin, especially when infection or occult hematologic disease is suspected</p>
          </list-item>
          <list-item>
            <p>Assessment of storage disorders, including glycogen storage disorders and iron deposition <xref ref-type="bibr" rid="article-145905.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145905.s3" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>The iliac crest is the primary site for obtaining bone marrow specimens. The specimen collection should include BMA, bone marrow cores for trephine biopsy, and blood clots following biopsy. Following the guidelines established by the College of American Pathologists (CAP) and the International Society of Laboratory Hematology (ISLH) helps ensure specimen reporting consistency and accuracy.<xref ref-type="bibr" rid="article-145905.r3">[3]</xref><xref ref-type="bibr" rid="article-145905.r4">[4]</xref></p>
      </sec>
      <sec id="article-145905.s4" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>Bone marrow specimen collection for evaluation typically involves 2 procedures: bone marrow aspiration (BMA) and bone marrow biopsy (BMB). These procedures are typically performed in an outpatient setting and are generally well-tolerated. BMA involves using a thin needle to withdraw a liquid bone marrow sample from the posterior iliac crest or, less commonly, sternum or other bones. BMB involves using a larger needle to obtain a solid core sample of bone marrow tissue along with a thin core of bone.</p>
        <p>A complete bone marrow laboratory examination requires different specimen types to yield complementary results. These specimen types include the following:</p>
        <p>
<bold>Bone Marrow Aspirates</bold>
</p>
        <p>The World Health Organization (WHO) recommends immediate bedside preparation of aspirate smears using the pull technique or crush film smear to reduce drying artifacts from the initial specimen obtained.<xref ref-type="bibr" rid="article-145905.r5">[5]</xref>&#x000a0;Aspirates for flow cytometry should be collected separately in sodium heparin tubes. In contrast, aspirates for molecular studies should be collected in ethylenediaminetetraacetic acid (EDTA) or sodium heparin tubes. Romanoswky stains such as Wright or Giemsa must be used on the aspirates before methanol preservation for ancillary studies. Beyond 2 hours, EDTA-fixed aspirates lose their original morphology and become less suitable for evaluating morphologic dysplasia.<xref ref-type="bibr" rid="article-145905.r6">[6]</xref></p>
        <p>
<bold>Bone Marrow Cores for Trephine Biopsy</bold>
</p>
        <p>Core biopsy specimens are best obtained after BMA to prevent aspirate contamination with peripheral blood. The same skin entry site may be used, though the aspiration area should be avoided. Imprint smears are obtained by touching the core biopsy specimens onto glass slides. These imprints are especially helpful when aspiration yields a dry tap, and quick preliminary staining is needed after the biopsy procedure.</p>
        <p>The most common fixative used during core biopsy sampling is neutral buffered formalin. Zinc formaldehyde and Bouin&#x02019;s fixative are good alternatives. Calcium salts can make tissues hard and brittle, making sectioning and staining difficult. Decalcification is thus necessary. EDTA is the preferred decalcification agent, as it can preserve nuclear acids for immunohistochemical staining. However, urgent cases, ie, needing a 6-hour decalcification time, require the Hammersmith protocol using 10% formic acid and 5% formaldehyde.<xref ref-type="bibr" rid="article-145905.r7">[7]</xref></p>
        <p>
<bold>Post-Biopsy Blood Clot</bold>
</p>
        <p>Clots obtained after trephine biopsy may provide additional insights. These clots are fixed in formalin and processed similarly to trephine biopsy specimens. Blood clots help assess marrow cellularity, cellular morphology, and atypical infiltrates, enabling immunohistochemical staining. As decalcification is not required, these samples are better suited for cytogenetics, FISH, and molecular testing. However, flow cytometric analysis cannot be performed on clot samples.</p>
      </sec>
      <sec id="article-145905.s5" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>BMA and BMB are often performed together to provide complementary information about the bone marrow's cellular composition and architecture. Below is a systematic approach to examining marrow aspirates and biopsies for a thorough bone marrow evaluation.</p>
        <p>
<bold>Bone Marrow Aspirate Analysis</bold>
</p>
        <p>Bone marrow aspirate is better suited for assessing cytomorphology, differential cell counts, and performing ancillary studies like flow cytometry, cytogenetics, and molecular testing. A stepwise approach to examining bone marrow aspirates is discussed below.</p>
        <p>
<bold>Low-power magnification</bold>
</p>
        <p>Low-power lenses typically provide 10 times object magnification. The adequacy and overall cellularity of the bone marrow can be appreciated in this setting.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Adequacy: </bold>An adequate bone marrow smear is characterized by numerous particles with trails of cytomorphologically well-defined and well-stained blood cells. The presence of megakaryocytes indicates a successful marrow tap. However, the tap is considered dilute if megakaryocytes are present without particles. In contrast, smears with stromal fragments lacking particles, megakaryocytes, and hematopoietic marrow elements are deemed inadequate and noted as &#x0201c;peripheral blood&#x0201d; or &#x0201c;bloody tap&#x0201d; on the report (see <bold>Image. </bold>Stromal Fragments).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cellular clusters:</bold> Metastatic carcinomas and benign marrow cells like plasma cells, osteoblasts, and macrophages can cluster in marrow aspirates. Identifying and further examining these clusters under high-power magnification allows for a detailed analysis of their cytologic features and accurate identification of specific cell types.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>High-power magnification</bold>
</p>
        <p>High-power lenses have a magnifying ability of at least 40 times. High-power magnification is ideal for assessing finer cellular morphological details, including nuclear-cytoplasmic ratio, chromatin pattern, and the presence of any abnormal inclusions, cytoplasmic granules, or parasites. High-power magnification is essential for identifying specific cell types, assessing cell maturation, and detecting morphologic dysplasia and abnormal cells like blasts.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cellularity:</bold>&#x000a0;"Cellularity" refers to the proportion of different cell types present in a bone marrow aspirate. CAP recommends&#x000a0;conducting a differential count of 500 cells. However, research suggests that a count of 300 cells may also suffice.<xref ref-type="bibr" rid="article-145905.r8">[8]</xref> The differential cell count includes myeloid (granulocytic and monocytic cells) and erythroid progenitors, lymphoid elements, and plasma cells. Megakaryocytes, histiocytes, mast cells, and nonhematopoietic cells are excluded from this count.&#x000a0;A normal myeloid-erythroid ratio falls between 2:1 and 4:1, but this ratio must be interpreted alongside PBS findings for a comprehensive assessment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Maturation:</bold> Cell maturation in the bone marrow is a continuous process. Increased immature cells, including blasts and blast equivalents such as promyelocytes and promonocytes, suggest a neoplastic process and warrant further investigation (see <bold>Image. </bold>Bone Marrow Aspirate with Blasts). Acute leukemias are defined by more than 20% blasts or blast equivalents in the bone marrow in the absence of leukemia-defining genetic abnormalities. If the blast count is less than 20%, WHO 2022 guidelines recommend that acute myeloid leukemia (AML) can be diagnosed if defined molecular aberrations accompany this finding. Different AML subtypes have differing morphologic features, immunophenotypes, and prognoses (see <bold>Table.</bold> Features of Genetically Defined AML).<xref ref-type="bibr" rid="article-145905.r9">[9]</xref> Despite well-defined molecular characteristics, certain AML subtypes with <italic toggle="yes">BCR-ABL1</italic> fusion and&#x000a0;<italic toggle="yes">CEBPA</italic> mutation still require more than 20% blasts for diagnosis. Although the boundaries between myelodysplastic neoplasms (MDS) and AML have softened, retaining a blast cutoff of 20% prevents overtreatment.<xref ref-type="bibr" rid="article-145905.r10">[10]</xref><xref ref-type="bibr" rid="article-145905.r11">[11]</xref></p>
          </list-item>
        </list>
        <table-wrap id="article-145905.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Features of Genetically Defined AML</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">
<p><bold>AML-defining genetic abnormality (&#x0003c; 20% blasts required for diagnosis)</bold></p>
</td>
                <td style="text-align: center;" rowspan="1" colspan="1">
<p><bold>Morphologic features</bold></p>
</td>
                <td style="text-align: center;" rowspan="1" colspan="1">
<p><bold>Immunophenotype</bold></p>
</td>
                <td style="text-align: center;" rowspan="1" colspan="1">
<p><bold> Prognosis</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>AML with <italic toggle="yes">RUNX1:: RUNX1T1</italic> fusion</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Neutrophilic maturation with occasional dysplasia</p></list-item><list-item><p>Blasts with occasional nuclear indentation and Auer rods</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Express CD34, CD117, CD13, CD33, and cytoplasmic MPO</p></list-item><list-item><p>Some expression of neutrophilic CD15/CD65</p></list-item><list-item><p>Aberrant expression of the B-cell-lineage marker CD19</p></list-item><list-item><p>CD56 is associated with a poor prognosis</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Adults: Favorable prognosis</p>
<p>Children: Poor prognosis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Acute promyelocytic leukemia (APL) with <italic toggle="yes">PML::RARA</italic> fusion</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Hypergranular promyelocytes with multiple Aeur rods&#x000a0;&#x000a0;&#x000a0;</p></list-item><list-item><p>Hypogranular promyelocytes with bilobed nucleus</p></list-item><list-item><p>Hyperbasophilic variant with cytoplasmic blebs</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Express CD13, CD33, and CD117 but negative for CD34 and HLADR</p></list-item><list-item><p>The leukemic cells are negative for CD15/CD16</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Excellent prognosis with prompt all-trans retinoic acid (ATRA) treatment</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>AML with <italic toggle="yes">CBFB::MYH11</italic> fusion</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Myelomonocytic leukemia with eosinophilic precursors</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Expression of monocytic lineage markers like CD4, CD36, and CD11b</p></list-item><list-item><p>Aberrant CD2 expression</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Favorable</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>AML with <italic toggle="yes">KMT2A</italic> rearrangements</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Usually, acute monoblastic leukemia&#x000a0;</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Expression or monocytic markers but not CD19</p></list-item><list-item><p>Usually lack CD34</p></list-item><list-item><p>No definite immunophenotype</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Poor</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>AML with <italic toggle="yes">DEK::NUP214</italic> fusion&#x000a0;&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Basophilic differentiation, with features of dysplasia</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>CD34, CD33, CD117, CD13, and CD38 expression</p></list-item><list-item><p>No definite immunophenotype</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Poor</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>AML with <italic toggle="yes">MECOM</italic> rearrangements</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Dysplastic megakaryocytes</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Expression of CD34, CD117, CD13, and CD33 but lacks MPO expression</p></list-item><list-item><p>CD41, CD42, and CD62 expression indicates megakaryocytic differentiation</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Poor</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>AML with <italic toggle="yes">NPM1</italic> fusion</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Nuclear indentation with a cup-shaped nucleus</p></list-item><list-item><p>Can show myeloblastic, monoblastic, or myelomonocytic differentiation</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Myeloblastic differentiation with CD33, CD117, and MPO expression</p></list-item><list-item><p>Monocytic differentiation with CD64, CD14 expression</p></list-item><list-item><p>One- to two-thirds of cases do not express CD34 AND HLA-DR</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Without <italic toggle="yes">FLT3</italic>-ITD-Favorable</p>
<p>With <italic toggle="yes">FLT3</italic>-ITD- Intermediate</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>AML with <italic toggle="yes">RBM15::MRTFA</italic> fusion</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Common in infants</p></list-item><list-item><p>Blasts with basophilic features and cytoplasmic blebs</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>CD41, CD42, CD61 expression</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Intermediate</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>AML with <italic toggle="yes">NUP98</italic> rearrangement</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rare, with a spectrum ranging from undifferentiated morphology to monocytic differentiation</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>No definite immunophenotype</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<p>Poor</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Dysplasia</bold>
</p>
        <p>Erythroid dysplasia is characterized by morphological abnormalities, including nuclear budding and lobation, internuclear bridges, karyorrhexis, binuclear and multinuclearity, cytoplasmic vacuolation, and megaloblastic changes, and the presence of ringed sideroblasts (see <bold>Image.</bold> Nuclear Budding).<xref ref-type="bibr" rid="article-145905.r12">[12]</xref> Nonneoplastic conditions like megaloblastic anemia, congenital dyserythropoietic anemia, copper deficiency, and zinc excess may also exhibit features of erythroid dysplasia. Ringed sideroblasts may be detected by iron-staining aspirate smears with particles. A semiquantitative score of 1 to 4 is used to evaluate the abundance of ringed sideroblasts.<bold>&#x000a0;</bold></p>
        <p>Granulocytic dysplasia&#x02019;s morphologic features include nuclear hypersegmentation and hyposegmentation (pseudo-Pelger-Hu&#x000eb;t neutrophils), decreased cytoplasmic granularity, D&#x000f6;hle bodies, and Auer rods.<xref ref-type="bibr" rid="article-145905.r13">[13]</xref> Nonneoplastic conditions, including vitamin B12 and folic acid deficiency, hepatitis C and human immunodeficiency virus (HIV) infection, autoimmune diseases like systemic lupus erythematosus, medications like granulocyte macrophage-colony stimulating factor, and hereditary Pelger-Hu&#x000eb;t anomaly can show morphologic features of granulocytic dysplasia. Using EDTA as an anticoagulant&#x02014;which lavender-top tubes contain&#x02014;can give rise to pseudo-dysplastic granulocytes but erythroid dyspoiesis.<xref ref-type="bibr" rid="article-145905.r14">[14]</xref>&#x000a0;</p>
        <p>Megakaryocytic dysplasia manifests with micromegakaryocytosis and megakaryocyte hypolobation, multinucleation, and clustering (aggregates with &#x0003e;6 megakaryocytes)(see <bold>Images.</bold> Dysplastic Megakaryocytes and Dysplastic Megakaryocytes, Hyperlobated). Neoplastic causes of megakaryocytic dysplasia include myeloproliferative neoplasms (MPN), myelodysplastic neoplasms (MDS), and MDS/MPN.</p>
        <p>Importantly, nonneoplastic causes should be ruled out in cases presenting with erythroid or granulocytic dysplasia before making a diagnosis of MDS. The dysplasia evaluation includes a comprehensive approach, starting with a detailed clinical history, CBC to assess for cytopenias, PBS examination, and biochemical and serological tests, including vitamin and serologic markers. Further investigations include a bone marrow examination, flow cytometry, cytogenetics, and molecular tests.</p>
        <p>In the 5th edition of WHO&#x02019;s 2022 myelodysplastic neoplasm classification, the term "myelodysplastic neoplasms" has replaced "myelodysplastic syndromes" while retaining the &#x0201c;MDS&#x0201d; abbreviation, aligning the nomenclature with myeloproliferative neoplasms for consistency. Lineage dysplasia can be progressive, indicating disease evolution. Distinguishing between unilineage and multilineage dysplasia is now optional.</p>
        <p>Accurate blast percentage determination in bone marrow and peripheral blood helps distinguish between various morphologically defined MDS subgroups. According to the WHO 2022 guidelines, MDS with specific genetic abnormalities are classified as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>MDS with low blasts and isolated del(5q): blasts &#x0003c;5% in the bone marrow and &#x0003c;2% in the peripheral blood</p>
          </list-item>
          <list-item>
            <p>MDS with low blasts and <italic toggle="yes">SF3B1</italic> mutation: blasts &#x0003c;5% in the bone marrow and &#x0003c;2% in the peripheral blood; the presence of &#x0003e;15% ringed sideroblasts obviates the need to find an <italic toggle="yes">SF3B1</italic> mutation</p>
          </list-item>
          <list-item>
            <p>MDS with bi-allelic <italic toggle="yes">TP53</italic> inactivation: &#x0003c;20% in bone marrow and peripheral blood</p>
          </list-item>
        </list>
        <p>A summary of morphologically defined MDS subgroups is provided below (see <bold>Table.</bold> Morphologically Defined MDS).<xref ref-type="bibr" rid="article-145905.r15">[15]</xref></p>
        <p>&#x000a0;<bold>Table 2.</bold> Morphologically Defined MDS</p>
        <table-wrap id="article-145905.table1" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td style="width: 285.422px;" rowspan="1" colspan="1">
<p><bold>Morphologically defined MDS, category</bold></p>
</td>
                <td style="width: 401.578px;" rowspan="1" colspan="1">
<p><bold>Blast percentage</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 285.422px;" rowspan="1" colspan="1">
<p>MDS with low blasts (MDS-LB)</p>
</td>
                <td style="width: 401.578px;" rowspan="1" colspan="1">
<p>&#x0003c;5% bone marrow and &#x0003c;2% peripheral blood</p>
</td>
              </tr>
              <tr>
                <td style="width: 285.422px;" rowspan="1" colspan="1">
<p>MDS, hypoplastic (MDS-h)</p>
</td>
                <td style="width: 401.578px;" rowspan="1" colspan="1">
<p>&#x0003c;5% bone marrow and &#x0003c;2% peripheral blood</p>
</td>
              </tr>
              <tr>
                <td style="width: 285.422px;" rowspan="1" colspan="1">
<p>MDS with increased blasts (MDS-IB)</p>
</td>
                <td style="width: 401.578px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 285.422px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>MDS-IB1</p></list-item></list>
</td>
                <td style="width: 401.578px;" rowspan="1" colspan="1">
<p>5-9% bone marrow or 2-4% peripheral blood</p>
</td>
              </tr>
              <tr>
                <td style="width: 285.422px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>MDS-IB2</p></list-item></list>
</td>
                <td style="width: 401.578px;" rowspan="1" colspan="1">
<p>10-19% bone marrow or 5-19% peripheral blood or Auer rods</p>
</td>
              </tr>
              <tr>
                <td style="width: 285.422px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>MDS with fibrosis (MDS-f)</p></list-item></list>
</td>
                <td style="width: 401.578px;" rowspan="1" colspan="1">
<p>5-19% bone marrow or 2-19% peripheral blood</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Lymphoma</bold>
</p>
        <p>Bone marrow examination is routinely used to stage lymphoid neoplasms. The presence of cells with blastoid morphology in the background of marrow lymphoglandular bodies should raise the possibility of lymphoma&#x000a0;rather than a myeloid neoplasm.<xref ref-type="bibr" rid="article-145905.r16">[16]</xref></p>
        <p>
<bold>Plasma cell neoplasms</bold>
</p>
        <p>According to the WHO 2022 guidelines, multiple myeloma is diagnosed when at least 10% of clonal plasma cells are detected in the bone marrow, accompanied by one or more myeloma-defining events. These events include clonal bone marrow plasmacytosis exceeding 60%, a serum-free light chain ratio of at least 100, or more than 1 focal lesion on imaging&#x000a0;(see <bold>Image.</bold> Bone Marrow Aspirate with Plasma Cells). Cytogenetic marrow aspirate evaluation is used for myeloma risk stratification. High-risk multiple myelomas are identified by the presence of t(14;16), t(14;20), t(4;14), del(17p), gain(1q), or p53 mutation. Myelomas with 2 or 3 of these high-risk cytogenetics are categorized as double- or triple-hit myelomas, respectively.<xref ref-type="bibr" rid="article-145905.r17">[17]</xref>&#x000a0;</p>
        <p>
<bold>Significance of other cell types</bold>
</p>
        <p>Mast cells may occasionally be observed in bone marrow aspirates and are discussed further below. Macrophages, usually rare, are primarily associated with erythroid islands and may contain hemosiderin.<xref ref-type="bibr" rid="article-145905.r18">[18]</xref> Increasing macrophages might indicate hemolytic anemias, inflammatory conditions, or neoplastic disorders such as myeloproliferative neoplasms.<xref ref-type="bibr" rid="article-145905.r19">[19]</xref> Erythrophagocytosis can be observed in immune hemolysis, hemophagocytic lymphohistiocytosis, and histiocytic neoplasms (see <bold>Image. </bold>Eyrthrophagocytosis). In lysosomal storage disorders like Gaucher disease, macrophages can accumulate lysosomal products, leading to a distinctive ''wrinkled tissue paper'' appearance.<xref ref-type="bibr" rid="article-145905.r20">[20]</xref></p>
        <p>
<bold>Bone Marrow Biopsy</bold>
</p>
        <p>Bone marrow trephine biopsy helps assess overall marrow cellularity and architecture, which are especially sensitive in detecting focal lesions. Core biopsy provides better insight into the relationship of bone marrow elements to each other.<xref ref-type="bibr" rid="article-145905.r21">[21]</xref> Below is a systematic approach for evaluating both marrow aspirates and biopsies for a thorough bone marrow evaluation.</p>
        <p>
<bold>Marrow cellularity</bold>
</p>
        <p>Bone marrow cellularity indicates the proportion of hematopoietic elements to both hematopoietic and mature adipose tissue. This value decreases with age. Neonatal marrows are highly cellular (90-100%), declining to 50% by age 30 and further diminishing to 30% by age 70. Subcortical bone marrow is physiologically hypocellular and not optimal for evaluating cellularity.<xref ref-type="bibr" rid="article-145905.r22">[22]</xref></p>
        <p>The correlation between trephine biopsy specimen and bone marrow aspirate cellularity is essential, as a hypercellular aspirate with unremarkable biopsy warrants further investigation. Conversely, a dry tap may indicate marrow fibrosis or infiltration, which is better appreciated on trephine biopsy.&#x000a0;</p>
        <p>
<bold>Cellular distribution</bold>
</p>
        <p>The distribution of maturing hematopoietic elements is better discerned in trephine biopsy sections. Erythroid cells typically cluster in the interstitium. Meanwhile, immature myeloid precursors reside in the paratrabecular spaces, progressing toward the interstitium as they mature. Megakaryocytes normally have a perisinusoidal distribution. Paratrabecular megakaryocyte growth signifies abnormal hematopoiesis.<xref ref-type="bibr" rid="article-145905.r23">[23]</xref></p>
        <p>Megakaryocytic clustering is a diagnostic feature indicative of marrow regeneration after bone marrow transplantation or chemotherapy. This feature is also a hallmark of various neoplastic conditions, particularly myeloproliferative neoplasms like primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV). Thus, this finding warrants further investigation.</p>
        <p>Normal bone marrow contains few interstitial lymphocytes and occasional well-circumscribed reactive lymphoid aggregates in non-paratrabecular locations. However, neoplastic lymphoid aggregates exhibit features such as paratrabecular and perisinusoidal distribution, B-cell predominance and infiltration, and adipose tissue involvement (see <bold>Image.</bold> Paratrabecular Lymphoid Aggregate). Marrow samples with increased benign lymphoid aggregation have increased plasmacytosis and lipid granuloma formation. These findings may be associated with autoimmune conditions like rheumatoid arthritis.<xref ref-type="bibr" rid="article-145905.r24">[24]</xref></p>
        <p>Diagnosing residual disease post-rituximab therapy becomes challenging due to resulting CD20 downregulation. PAX-5 and CD79a are alternative B-cell markers for evaluating residual disease following therapy.<xref ref-type="bibr" rid="article-145905.r25">[25]</xref><xref ref-type="bibr" rid="article-145905.r26">[26]</xref> Lymphoid aggregates may be present in MDS, myeloproliferative neoplasms, and lymphomatous marrow infiltration.</p>
        <p>Lymphomatous bone marrow involvement can exhibit different patterns: focal (paratrabecular) pattern observed in follicular lymphomas and mantle cell lymphomas and non-paratrabecular pattern in chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and Hodgkin lymphoma (HL). Diffuse solid and interstitial patterns are seen in aggressive and blastic lymphomas. Intravascular patterns are found in splenic marginal zone lymphoma and intrasinusoidal large cell lymphoma.<xref ref-type="bibr" rid="article-145905.r27">[27]</xref> Studies indicate that 11.4% to 37% of B-cell lymphomas, 16% to 25% of T-cell lymphomas, and up to 11.8% of HL involve the bone marrow.<xref ref-type="bibr" rid="article-145905.r28">[28]</xref><xref ref-type="bibr" rid="article-145905.r29">[29]</xref>&#x000a0;</p>
        <p>Mast cells are identifiable by their metachromatic granules, best visualized using Giemsa and toluidine-blue stains (see <bold>Image. </bold>Mast Cells). Atypical mast cells appear as spindle cells with a monocytoid nucleus, hypogranular cytoplasm, and paratrabecular location.</p>
        <p>Increased mast cells in the marrow are observed in conditions such as aplastic anemia, CLL, hairy cell leukemia, impending blast crisis in chronic myeloid leukemia, systemic mastocytosis, mast cell sarcoma, and lymphoplasmacytic lymphoma. Neoplastic mast cells show aberrant CD25, CD30, and CD2 expression. Systemic mastocytosis is associated with an activating KITD816V mutation present in more than 90% of cases.<xref ref-type="bibr" rid="article-145905.r30">[30]</xref></p>
        <p>
<bold>Focal pathology detection</bold>
</p>
        <p>Neoplastic lymphoid aggregates, plasma cells, clusters of mast cells, and metastases can be focal processes. (see <bold>Image.</bold> Metastatic Carcinoma). Examining multiple tissue levels helps evaluate for focal pathology, especially when clinically indicated.</p>
        <p>Nonhematopoietic malignancies that most commonly metastasize to the bone marrow originate from the breast, prostate, kidney, thyroid, and gastrointestinal tract.<xref ref-type="bibr" rid="article-145905.r31">[31]</xref>&#x000a0;To identify subtle tumor cell infiltration, a keratin stain is recommended in patients with a known epithelial cancer history and suspected bone metastases.</p>
        <p>
<bold>Dysplasia</bold>
</p>
        <p>Megakaryocytic dysplasia is often characterized by atypical megakaryocyte morphology and clustering and is best evaluated through trephine biopsies. In the normal marrow, megakaryocytes are usually found solitary in non-paratrabecular locations. However, megakaryocytes cluster in paratrabecular and perisinusoidal locations in myeloproliferative neoplasms and PMF but are more scattered in ET (see <bold>Image. </bold>Dysplastic Megakaryocytes).</p>
        <p>A highly specific dysplastic MDS feature is micromegakaryocytosis, considered pathognomonic for this condition. Morphologically, ET megakaryocytes appear large with a staghorn-like nucleus, while those in PMF exhibit cloud-like, hypolobated nuclei with hyperchromasia and a decreased nuclear-cytoplasmic ratio (see <bold>Image. </bold>Primary Myelofibrosis).<xref ref-type="bibr" rid="article-145905.r32">[32]</xref></p>
        <p>Overlapping clinicopathologic features among Philadelphia-negative myeloproliferative neoplasms (eg, PV, ET, and PMF) suggest a common JAK/STAT genetic pathway, with <italic toggle="yes">JAK2, CALR</italic>, and <italic toggle="yes">MPL</italic>&#x000a0;being 3&#x000a0;of the most common driver mutations. Distinguishing PMF from PV and ET is crucial, as PMF is associated with a higher fibrosis incidence and acute leukemia progression. Bone marrow biopsy is critical in diagnosing and detecting leukemic transformation and fibrotic progression. Immunohistochemical stains such as CD34 are&#x000a0;highly useful for determining blast counts, particularly in cases of marrow fibrosis.<xref ref-type="bibr" rid="article-145905.r33">[33]</xref></p>
        <p>
<bold>Fibrosis</bold>
</p>
        <p>Bone marrow fibrosis is a common cause of dry tap and contributes to discordances between aspirate and marrow findings. Fibrosis can arise from nonneoplastic conditions like bone marrow necrosis, metastatic nonhematopoietic malignancies, lymphoma infiltration, and myeloproliferative neoplasms, including PMF, post-ET, and PV.</p>
        <p>Reticulin staining helps determine the extent of fibrosis in the marrow microenvironment, which is graded as follows:<xref ref-type="bibr" rid="article-145905.r34">[34]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>MF-0: Normal bone marrow with a scattered linear reticulin pattern but without intersections&#x000a0;</p>
          </list-item>
          <list-item>
            <p>MF-1: Loose reticulin network with numerous intersections, predominantly in perivascular regions&#x000a0;</p>
          </list-item>
          <list-item>
            <p>MF-2: Dense and diffuse increased reticulin with extensive intersections, occasionally interspersed with focal collagen bundles or focal osteosclerosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>MF-3: Dense and diffuse increased reticulin with extensive intersections, coarse collagen bundles, and significant osteosclerosis (see <bold>Image.</bold> Grade 3 Bone Marrow Fibrosis)</p>
          </list-item>
        </list>
        <p>
<bold>Necrosis</bold>
</p>
        <p>Bone marrow necrosis is a rare, potentially fatal complication that may arise from hematopoietic malignancies like myeloproliferative neoplasms, leukemias, lymphomas, and plasma cell myelomas. Chemotherapy and treatment with retinoic acid and granulocyte colony-stimulating factor increase the risk of bone marrow necrosis (see <bold>Image.</bold> Bone Marrow Necrosis). This condition can also occur after infections like parvovirus (especially in sickle cell patients) and HIV or the use of medications like sulfasalazine, interferon, and imatinib.<xref ref-type="bibr" rid="article-145905.r35">[35]</xref> Distinguishing bone marrow necrosis from conditions like aplastic anemia, extensive amyloid deposition, and gelatinous transformation is vital to patient management.<xref ref-type="bibr" rid="article-145905.r36">[36]</xref>&#x000a0;</p>
        <p>
<bold>Granulomas</bold>
</p>
        <p>Macrophage infiltration and granulomatous inflammation often pose diagnostic challenges. Exclusion of CD68-expressing mast cells mimicking granulomas is essential. Granulomas may be associated with diseases like HL but do not necessarily indicate direct lymphomatous bone marrow infiltration.<xref ref-type="bibr" rid="article-145905.r26">[26]</xref></p>
        <p>
<bold>Discordance Between Aspirate and Bone Marrow Trephine Biopsy</bold>
</p>
        <p>Discrepancies between the results of bone marrow aspirate and trephine biopsy samples occur frequently. Bone marrow aspirate criteria for the morphological assessment of blasts and erythroid or granulocytic dysplasia are&#x000a0;more clearly&#x000a0;defined than biopsy criteria. Focal lesions such as lymphoid and plasma cell aggregation, metastatic carcinomas, and dysplastic megakaryocyte growth can be underrepresented in aspirates and better appreciated on trephine biopsies. Dry marrow taps attributed to pathologies like myelofibrosis, aplastic anemia, and metastatic carcinoma infiltration are also better visualized on trephine biopsy.</p>
        <p>Correlating BMA and BMB findings is crucial. The general guideline is that pathologies visible on the aspirate should also be identifiable on biopsies. However, the reverse may not always be accurate, emphasizing the importance of thorough clinicopathologic correlation in diagnosis.<xref ref-type="bibr" rid="article-145905.r26">[26]</xref></p>
        <p>
<bold>Bone Marrow Evaluation in Clonal Hematopoiesis&#x000a0;</bold>
</p>
        <p>Clonal hematopoiesis (CH) denotes the presence of cells arising from a mutated progenitor cell and exhibiting a propensity for proliferation in the absence of unexplained cytopenias, hematologic malignancies, or other clonal disorders.<xref ref-type="bibr" rid="article-145905.r11">[11]</xref> The WHO 2022 has defined 2 categories:</p>
        <list list-type="bullet">
          <list-item>
            <p>"Clonal hematopoiesis of indeterminate potential" (CHIP) refers to cases where CH with myeloid-malignancy-associated somatic gene mutations is observed at a variant allele fraction of more than 2%. Individuals with CHIP lack a diagnosed hematologic malignancy or unexplained cytopenia. The significance of a variant allele frequency (VAF) of less than 2% is currently unclear.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>"Clonal cytopenia of undetermined significance" (CCUS) refers to CH with at least 1 persistent cytopenia lasting longer than 4 months. These cytopenias are unexplained by any hematologic or systemic condition and do not meet the diagnostic criteria for defined myeloid malignancies. The peripheral blood criteria for CCUS, MDS, and MDS/MPN include the following:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Hemoglobin less than 13 g/dL in male individuals and less than 12 g/dL in female individuals</p>
              </list-item>
              <list-item>
                <p>Absolute neutrophil count less than 1,800/mm&#x000b3;</p>
              </list-item>
              <list-item>
                <p>Platelet count less than 150,000/mm&#x000b3;</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Bone marrow evaluation in CH requires a thorough understanding of the patient's clinical presentation and close collaboration between hematology and hematopathology teams. Excluding an underlying hematologic myeloid neoplasm requires an interprofessional approach.</p>
        <p>
<bold>Ancillary Studies</bold>
</p>
        <p>Ancillary bone marrow studies include immunohistochemistry, flow cytometry, cytogenetics, FISH, polymerase chain reaction (PCR), and next-generation sequencing (NGS). The upcoming sections delve into these studies&#x02019; substantial impact on patient management.</p>
      </sec>
      <sec id="article-145905.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Molecular genetics have become pivotal for diagnosing, classifying, prognosticating, and treating hematopoietic malignancies. Certain neoplasms are now defined by molecular alterations, making molecular testing indispensable. Cytogenetics and FISH were traditionally used merely for chromosomal studies. Presently, NGS&#x000a0;may be employed to detect significant somatic mutations.</p>
        <p>Summarized below are the various hematopoietic conditions&#x02019; primary defining molecular pathways and mutations and their prognostic and clinical significance (see <bold>Table.</bold> Myeloproliferative, Eosinophilic, and Mast Cell Neoplasms).<xref ref-type="bibr" rid="article-145905.r37">[37]</xref><xref ref-type="bibr" rid="article-145905.r38">[38]</xref></p>
        <table-wrap id="article-145905.table2" position="float" orientation="portrait">
          <caption>
            <title>Table 3. Myeloproliferative, Eosinophilic, and Mast Cell Neoplasms</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Disease</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Major genetic pathway/defining mutation</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Mutations with prognostic significance</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Clinical and therapeutic implications</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Chronic myeloid leukemia (CML)</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">BCR</italic>::<italic toggle="yes">ABL1</italic> fusion resulting from t(9;22)(q34;q11)</p>
</td>
                <td rowspan="1" colspan="1">
<p>FISH or RT-PCR in PB samples</p>
<p>Myeloid panel testing for non-tyrosine kinase mutations (<italic toggle="yes">IKZH1</italic> deletions, <italic toggle="yes">RUNX1</italic> and <italic toggle="yes">ASXL1</italic> mutations) conferring drug resistance</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">BCR</italic>::<italic toggle="yes">ABL1</italic> transcript levels determine response to treatment and therapeutic decisions</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Polycythemia vera (PV)</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">JAK2 p.V617F</italic> or <italic toggle="yes">JAK2</italic> exon 12 mutations</p>
</td>
                <td rowspan="1" colspan="1">
<p>An increase in VAF from baseline indicates progression to post-PV myelofibrosis.&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>Higher <italic toggle="yes">JAK2</italic> VAF is associated with older age, high hemoglobin, low platelet count, and leukocytosis.</p>
<p>Therapies like interferon need mutation burden serial measurements to predict treatment outcomes, so VAF reporting is recommended.</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Essential thrombocythemia (ET)</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">JAK2, MPL, CALR</italic></p>
</td>
                <td rowspan="1" colspan="1">
<p>An increase in VAF from baseline indicates progression to post-ET myelofibrosis.&#x000a0;&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>NGS is recommended in <italic toggle="yes">JAK2-, MPL-</italic>, and <italic toggle="yes">CALR</italic>-negative patients to identify rare somatic variants (eg, noncanonical somatic <italic toggle="yes">MPL</italic> and <italic toggle="yes">JAK2 </italic>mutations).</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Primary myelofibrosis</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">JAK2, MPL, CALR</italic></p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">EZH2, IDH1, IDH2, CBL, KRAS, NRAS, TP53</italic> associated with poor prognosis</p>
</td>
                <td rowspan="1" colspan="1">
<p>NGS is recommended in <italic toggle="yes">JAK2-, MPL-</italic>, and <italic toggle="yes">CALR</italic>-negative patients to identify rare somatic variants (eg, noncanonical somatic <italic toggle="yes">MPL</italic> and <italic toggle="yes">JAK2 </italic>mutations).</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Chronic neutrophilic leukemia (CNL)</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">CSF3R</italic> mutations</p>
</td>
                <td rowspan="1" colspan="1">
</td>
                <td rowspan="1" colspan="1">
<p>Dasatinib is sensitive in CNLs with <italic toggle="yes">CSF3R</italic> mutations outside the proximal membrane region.</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Chronic eosinophilic leukemia, NOS</p>
</td>
                <td rowspan="1" colspan="1">
<p>Lack of criteria for any other myeloid or lymphoid neoplasm</p>
</td>
                <td rowspan="1" colspan="1">
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">PDGFRA</italic> (4q12), <italic toggle="yes">PDGFRB</italic>(5q31-33), <italic toggle="yes">FLT3</italic> (13q12), <italic toggle="yes">FGFR1</italic> (8p11) and <italic toggle="yes">JAK2</italic>(9p24) rearrangements should be absent</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Juvenile myelomonocytic leukemia (now classified as MPN)</p>
</td>
                <td rowspan="1" colspan="1">
<p>90% involve somatic activation of the RAS signaling pathway, including <italic toggle="yes">PTPN11, KRAS, and NRAS.</italic></p>
</td>
                <td rowspan="1" colspan="1">
<p>Germline <italic toggle="yes">NF1 </italic>mutation: aggressive behavior</p>
<p>Germline <italic toggle="yes">CBL </italic>mutation: spontaneous regression</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Systemic mastocytosis&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">KITpD816V</italic> mutation</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">SRSF, ASXL1</italic>, or <italic toggle="yes">RUNX1</italic> somatic mutations are identified by NGS and are associated with a poor prognosis.</p>
<p>Bone marrow samples used for greater sensitivity</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Neoplasms with eosinophilia</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">FIP1L1::PDGFRA</italic> (most common)</p>
<p><italic toggle="yes">PDGFRA</italic> (4q12), <italic toggle="yes">PDGFRB </italic>(5q31-33), <italic toggle="yes">FLT3</italic> (13q12), <italic toggle="yes">FGFR1</italic>(8p11) and <italic toggle="yes">JAK2</italic>(9p24) rearrangements</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">ETKN1, RUNX1, ASXL1, EZH2</italic> have a poor prognosis&#x000a0;</p>
<p><italic toggle="yes">FIP1L1::PDGFRA</italic> can be detected by FISH, NGS, or RT-PCR</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">KITD816V</italic> suggestive of systemic mastocytosis as a cause of eosinophilia&#x000a0;</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="article-145905.table3" position="float" orientation="portrait">
          <caption>
            <title>Table 4. Myelodysplastic neoplasms and MDS/MPNs</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p>Disease</p>
</td>
                <td rowspan="1" colspan="1">
<p>Primary genetic pathway/defining mutation</p>
</td>
                <td rowspan="1" colspan="1">
<p>Mutations with prognostic significance</p>
</td>
                <td rowspan="1" colspan="1">
<p>Clinical/Therapeutic implications</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>MDS with low blasts and isolated del 5q</p>
</td>
                <td rowspan="1" colspan="1">
<p>5q deletion alone or with one other cytogenetic abnormality besides 7q deletion or monosomy 7</p>
</td>
                <td rowspan="1" colspan="1">
<p>Biallelic <italic toggle="yes">TP53</italic> inactivation places&#x000a0;this mutation in the <italic toggle="yes">TP53</italic> inactivation subtype</p>
</td>
                <td rowspan="1" colspan="1">
<p>Lenalidomide licensed for use in MDS with del(5q)</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>MDS with low blasts and <italic toggle="yes">SF3B1</italic> mutation</p>
</td>
                <td rowspan="1" colspan="1">
<p>Presence of <italic toggle="yes">SF3B1</italic> mutation</p>
<p>Absence of monosomy 7, 5q deletion, or a complex karyotype</p>
</td>
                <td rowspan="1" colspan="1">
<p>Biallelic <italic toggle="yes">TP53</italic> inactivation places this mutation in the <italic toggle="yes">TP53</italic> inactivation subtype</p>
<p>&#x0003e;15% sideroblasts negates the need to find <italic toggle="yes">SF3B1</italic> mutation</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>MDS with biallelic <italic toggle="yes">TP53</italic> inactivation</p>
</td>
                <td rowspan="1" colspan="1">
<p>Two or more <italic toggle="yes">TP53</italic> mutations or the presence of one <italic toggle="yes">TP53</italic> copy number loss</p>
<p>Usually complex karyotype</p>
</td>
                <td rowspan="1" colspan="1">
</td>
                <td rowspan="1" colspan="1">
<p>This category can be considered as an AML equivalent from a therapeutic standpoint.</p>
<p><italic toggle="yes">TP53</italic> mutations are associated with increased therapeutic response to hypomethylating agents and shorter survival following allogenic stem-cell transplantation.</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Chronic Myelomonocytic Leukemia</p>
</td>
                <td rowspan="1" colspan="1">
<p>The presence of a clonal mutation is part of the supporting diagnostic criteria, with <italic toggle="yes">TET2</italic> and <italic toggle="yes">SRSF2</italic> biallelic variants showing high specificity.</p>
</td>
                <td rowspan="1" colspan="1">
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">SETBP1, RUNX1, NRAS,</italic> and <italic toggle="yes">ASXL1</italic> analyses are strongly recommended for transplantation-eligible individuals.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The prognosis of various genetically defined AMLs has been stated above (see <bold>Table 1. </bold>Features of Genetically Defined AML). Optimizing treatment strategies requires identifying targetable mutations like FLT3-ITD, IDH-1, and IDH2 by techniques such as PCR or capillary electrophoresis. AML cases with <italic toggle="yes">TP53</italic> mutation, specifically with a VAF exceeding 10%, are now denoted as "AML with mutated <italic toggle="yes">TP53</italic>." The mutation is associated with an unfavorable prognosis despite aggressive therapeutic interventions.<xref ref-type="bibr" rid="article-145905.r10">[10]</xref>&#x000a0;</p>
        <p>Posttreatment minimal residual disease (MRD) monitoring identifies impending relapse and facilitates early interventions. Multiparameter flow cytometry and molecular techniques like PCR and NGS can now be performed on peripheral blood and bone marrow samples. Notably, bone marrow samples offer higher sensitivity in MRD evaluation.</p>
        <p>NGS can provide information about preleukemic clones like <italic toggle="yes">DNMT3A, TET2,</italic> and <italic toggle="yes">ASXL1. </italic>These mutations may not be detectable during initial diagnosis but could become apparent through NGS. Importantly, the presence of these mutations does not necessarily predict disease relapse. Meanwhile, mutations like <italic toggle="yes">NPM1, RUNX1::RUNX1T1</italic>, and <italic toggle="yes">CBFB::MYH11</italic> are usually present at diagnosis and persist through relapse. Mutations like <italic toggle="yes">FLT3-ITD, NRAS</italic>, and <italic toggle="yes">KRAS</italic> may exhibit outcome variability following therapeutic interventions.<xref ref-type="bibr" rid="article-145905.r37">[37]</xref></p>
        <p>Acute lymphoid leukemia subtypes are also defined based on molecular genetics in the WHO 2022 classification. Cytogenetics and FISH are efficient diagnostic tools for identifying the defining chromosomal alterations (eg, <italic toggle="yes">BCR::ABL1, KMT2A::AFF1, ETVG::RUNX1, TCF3::PBX1, </italic>and<italic toggle="yes"> iAMP21</italic>), and prognostic factors like aneuploidy.<xref ref-type="bibr" rid="article-145905.r37">[37]</xref></p>
        <p>The ICSH and CAP advocate formulating an &#x0201c;Integrated Diagnosis,&#x0201d; which combines analysis of the peripheral blood, bone marrow aspirate, and trephine biopsy with ancillary and molecular testing. An integrated diagnosis aims to classify hematopoietic neoplasms as currently defined by the WHO and provide hematologists with pertinent information to help determine management. These insights are instrumental in devising tailored and effective therapeutic strategies and optimizing overall treatment outcomes.</p>
        <p>The information that must be included in a comprehensive bone marrow examination report are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Institutional Information</bold>
<list list-type="bullet"><list-item><p>Institution&#x02019;s name&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Patient Details</bold>
<list list-type="bullet"><list-item><p>Patient's name</p></list-item><list-item><p>Birth date</p></list-item><list-item><p>Medical record number</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Requesting Physician</bold>
<list list-type="bullet"><list-item><p>Physician&#x02019;s name</p></list-item><list-item><p>Medical license number</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Procedure Details</bold>
<list list-type="bullet"><list-item><p>Procedure date</p></list-item><list-item><p>Indication for bone marrow examination</p></list-item><list-item><p>Procedure type (aspirate, trephine biopsy)</p></list-item><list-item><p>Procedure site (iliac crest, sternum, etc)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Peripheral Blood Smear</bold>
<list list-type="bullet"><list-item><p>CBC parameters</p></list-item><list-item><p>Peripheral blood smear description</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Bone Marrow Aspirate Examination</bold>
<list list-type="bullet"><list-item><p>Morphologic findings: cellularity, nucleated differential cell count, myeloid: erythroid ratio, blast percentages, erythropoiesis, myelopoiesis, megakaryocytes, lymphocytes, plasma cells, other hematopoietic cells, abnormal cells</p></list-item><list-item><p>Special stains: iron stain, cytochemistry</p></list-item><list-item><p>Other investigations: cytogenetics, FISH, PCR, and molecular methods, including NGS</p></list-item><list-item><p>Flow cytometry results (if performed)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Bone Marrow Trephine Biopsy Examination</bold>
<list list-type="bullet"><list-item><p>Morphologic findings: length of core biopsy, cellularity, bone architecture, location, number, morphology, and maturation of erythroid, myeloid and megakaryocyte lineages, plasma cells, lymphocytes, and macrophages; abnormal cells or infiltrates.</p></list-item><list-item><p>Special stains: Reticulin stain</p></list-item><list-item><p>Immunohistochemistry results</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Final Integrated Diagnosis per WHO Criteria</bold>
<list list-type="bullet"><list-item><p>Summary of findings</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Note</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Signature and date of reporting</bold>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145905.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bone marrow examination is an indispensable tool in the diagnosis and posttreatment monitoring of hematopoietic conditions. Developing a systematic bone marrow evaluation approach and establishing a standardized reporting methodology, including molecular studies, is essential. These practices help promote a better understanding of the terminology and behavior of hematopoietic neoplasms, thus fostering efficient collaboration within interprofessional teams caring for patients with hematopoietic disorders.</p>
        <p>The interprofessional team members in these cases include pathologists, hematologists, oncologists, primary care physicians, nurses, and pharmacists. Pathologists provide accurate diagnostic assessments based on bone marrow samples. Hematologists oversee patient management and treatment strategies tailored to specific blood disorders. Oncologists administer specialized cancer care, including chemotherapy regimens.</p>
        <p>Primary care physicians coordinate overall patient care and ensure continuity beyond specialty settings. Nurses and pharmacists support patient care, administer treatments, and manage side effects. Laboratory analysts process and&#x000a0;evaluate&#x000a0;bone marrow samples, contributing to accurate diagnostic reports. Together, these healthcare professionals ensure comprehensive care and optimal treatment outcomes for patients undergoing bone marrow examination.</p>
      </sec>
      <sec id="article-145905.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145905&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145905">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/145905/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=145905">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-145905.s9">
        <fig id="article-145905.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Stromal Fragments. Hemodiluted bone marrow aspirate showing stromal fragments (with Leishman &#x00026; Giemsa stain&#x000a0;and 1000x magnification). Contributed by Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Dry__tap" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s10">
        <fig id="article-145905.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Bone Marrow Aspirate with Blasts. This image shows immature cells with a high nuclear-to-cytoplasmic ratio, scant cytoplasm, and immature nuclear chromatin with prominent nucleoli. Contributed by Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Blast" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s11">
        <fig id="article-145905.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Dysplastic Megakaryocytes, Hyperlobated. Bone marrow aspirate showing large megakaryocytes with hyperlobated forms (with Leishman &#x00026; Giemsa stain,&#x000a0;magnified 1000x). Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Megakaryocyte__dysplasya" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s12">
        <fig id="article-145905.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Dysplastic Megakaryocytes. Bone marrow aspirate showing scattered dysplastic megakaryocytes. Contributed by Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Megakaryocyte__dysplasia" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s13">
        <fig id="article-145905.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Bone Marrow Aspirate with Plasma Cells.&#x000a0;Bone marrow aspirate with sheets of plasma cells&#x000a0;in binucleate and multinucleate forms. Plasma cells have eccentric cytoplasm, perinuclear hof (clearing), and a dispersed (clock-faced) chromatin. Contributed by Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PLASMA__CELLS" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s14">
        <fig id="article-145905.image.f6" position="float" orientation="portrait">
          <caption>
            <p>Paratrabecular Lymphoid Aggregate. This bone marrow biopsy shows paratrabecular lymphoid aggregation. Contributed by Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Lymphoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s15">
        <fig id="article-145905.image.f7" position="float" orientation="portrait">
          <caption>
            <p>Primary Myelofibrosis. Bone marrow biopsy showing clusters of atypical megakaryocytes with cloud-like and balloon-shaped nuclei (with hematoxylin &#x00026; eosin stain, magnification 400x). Contributed by Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PMF__40x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s16">
        <fig id="article-145905.image.f8" position="float" orientation="portrait">
          <caption>
            <p>Grade 3 Bone Marrow Fibrosis. Bone marrow&#x000a0;specimen showing a diffuse and dense reticulin increase&#x000a0;and areas of collagenization. These findings are&#x000a0;characteristic of grade 3 myelofibrosis or MF-3 (with reticulin stain, magnified 400x) Contributed by Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Fibrosis__grade__3-__Reticulin__stain__" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s17">
        <fig id="article-145905.image.f9" position="float" orientation="portrait">
          <caption>
            <p>Bone Marrow Necrosis. This bone marrow biopsy&#x000a0;shows necrosis with loss of hematopoietic marrow and fat spaces. Bony trabeculae are preserved. Contributed by Swachi Jain, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NECROSIS" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s18">
        <fig id="article-145905.image.f10" position="float" orientation="portrait">
          <caption>
            <p>Mast Cells. Bone marrow aspirate showing a mast cell with granular cytoplasm&#x000a0;containing dense basophilic granules. Uday Kumar DS, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Mast__cells" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s19">
        <fig id="article-145905.image.f11" position="float" orientation="portrait">
          <caption>
            <p>Metastatic Carcinoma. Bone marrow biopsy showing infiltration by epithelial cells with signet ring morphology. Udaya Kumar DS, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Metastatic__carcinoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s20">
        <fig id="article-145905.image.f12" position="float" orientation="portrait">
          <caption>
            <p>Nuclear Budding. Bone marrow aspirate showing erythroid dysplasia. Udaya Kumar DS, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Dyserythropoiesis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145905.s21">
        <fig id="article-145905.image.f13" position="float" orientation="portrait">
          <caption>
            <p>Erythrophagocytosis. Bone marrow aspirate showing erythrophagocytosis. Udaya Kumar DS, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HLH" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-145905.s22">
        <title>References</title>
        <ref id="article-145905.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh Rana</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic value of bone marrow aspiration and biopsy in routine hematology practice.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>FC13</fpage>
            <page-range>FC13-6</page-range>
            <pub-id pub-id-type="pmid">25302200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rindy</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <chapter-title>Bone Marrow Aspiration and Biopsy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">32644658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Erber</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Porwit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>LC</given-names>
              </name>
              <collab>International Council for Standardization In Hematology</collab>
            </person-group>
            <article-title>ICSH guidelines for the standardization of bone marrow specimens and reports.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>349</fpage>
            <page-range>349-64</page-range>
            <pub-id pub-id-type="pmid">18822060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sever</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>de Baca</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Reichard</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terebelo</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Colasacco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rumble</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>140</volume>
            <issue>9</issue>
            <fpage>932</fpage>
            <page-range>932-49</page-range>
            <pub-id pub-id-type="pmid">26905483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sachdeva</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Varma</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Bone marrow aspirate smear preparation: morphological superiority of the timely wedge smear and the importance of imprints.</article-title>
            <source>Ann Hematol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>93</volume>
            <issue>6</issue>
            <fpage>1063</fpage>
            <page-range>1063-4</page-range>
            <pub-id pub-id-type="pmid">24141334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riley</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harley</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chesney</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A Synoptic Reporting System to Monitor Bone Marrow Aspirate and Biopsy Quality.</article-title>
            <source>J Pathol Inform</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">34447603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torlakovic</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Brynes</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Hyjek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kreipe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sadahira</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tzankov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Porwit</surname>
                <given-names>A</given-names>
              </name>
              <collab>International Council for Standardization in Haematology</collab>
            </person-group>
            <article-title>ICSH guidelines for the standardization of bone marrow immunohistochemistry.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>431</fpage>
            <page-range>431-49</page-range>
            <pub-id pub-id-type="pmid">25977137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdulrahman</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Sivers</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Jaye</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Is a 500-Cell Count Necessary for Bone Marrow Differentials?: A Proposed Analytical Method for Validating a Lower Cutoff.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2018</year>
            <month>May</month>
            <day>31</day>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-91</page-range>
            <pub-id pub-id-type="pmid">29757362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.</article-title>
            <source>Am J Hematol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>98</volume>
            <issue>3</issue>
            <fpage>481</fpage>
            <page-range>481-492</page-range>
            <pub-id pub-id-type="pmid">36606297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhansali</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Pratz</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in targeted therapies in acute myeloid leukemia.</article-title>
            <source>J Hematol Oncol</source>
            <year>2023</year>
            <month>Mar</month>
            <day>25</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <pub-id pub-id-type="pmid">36966300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoury</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Solary</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abla</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Akkari</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Alaggio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Apperley</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Bejar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Busque</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JKC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Colmenero</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>NCP</given-names>
              </name>
              <name>
                <surname>De Jong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elghetany</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Emile</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fogelstrand</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fontenay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Germing</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gujral</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haferlach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kanagal-Shamanna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kratz</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Loeb</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Loghavi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marcogliese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meshinchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Michaels</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Naresh</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Natkunam</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nejati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Padron</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Patkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Picarsic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Platzbecker</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schuh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sewell</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tembhare</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tyner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verstovsek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hochhaus</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic&#x000a0;Neoplasms.</article-title>
            <source>Leukemia</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>1703</fpage>
            <page-range>1703-1719</page-range>
            <pub-id pub-id-type="pmid">35732831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goasguen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Brunning</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vallespi</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Renault</surname>
                <given-names>A</given-names>
              </name>
              <collab>(The International Working Group on Morphology of MDS)</collab>
            </person-group>
            <article-title>Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas.</article-title>
            <source>Br J Haematol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>182</volume>
            <issue>4</issue>
            <fpage>526</fpage>
            <page-range>526-533</page-range>
            <pub-id pub-id-type="pmid">29917221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shekhar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>How I investigate dysgranulopoiesis.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>538</fpage>
            <page-range>538-546</page-range>
            <pub-id pub-id-type="pmid">34031992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>van der Weyden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mayson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Excessive EDTA induces morphologic changes in bone marrow smears that mimic specific features of dysplasia.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-9</page-range>
            <pub-id pub-id-type="pmid">23062172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoff</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Madanat</surname>
                <given-names>YF</given-names>
              </name>
            </person-group>
            <article-title>Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.</article-title>
            <source>Cells</source>
            <year>2023</year>
            <month>Feb</month>
            <day>15</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">36831294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gajendra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sachdev</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Lymphoglandular bodies in bone marrow aspirate smears.</article-title>
            <source>Blood Res</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">28401093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>97</volume>
            <issue>8</issue>
            <fpage>1086</fpage>
            <page-range>1086-1107</page-range>
            <pub-id pub-id-type="pmid">35560063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heideveld</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van den Akker</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Digesting the role of bone marrow macrophages on hematopoiesis.</article-title>
            <source>Immunobiology</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>222</volume>
            <issue>6</issue>
            <fpage>814</fpage>
            <page-range>814-822</page-range>
            <pub-id pub-id-type="pmid">27890297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadahira</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Manabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yawata</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Immunohistochemical assessment of human bone marrow macrophages in hematologic disorders.</article-title>
            <source>Pathol Int</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>7</issue>
            <fpage>626</fpage>
            <page-range>626-32</page-range>
            <pub-id pub-id-type="pmid">10504523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreira</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Lysosomal storage diseases.</article-title>
            <source>Transl Sci Rare Dis</source>
            <year>2017</year>
            <month>May</month>
            <day>25</day>
            <volume>2</volume>
            <issue>1-2</issue>
            <fpage>1</fpage>
            <page-range>1-71</page-range>
            <pub-id pub-id-type="pmid">29152458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merzianu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Groman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hutson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cotta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brynes</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Orazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Teruya-Feldstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amre</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Balasubramanian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brandao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cherian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Courville</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Czuchlewski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoehn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Inamdar</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Juskevicius</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lazarchick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Miles</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Qureishi</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Olteanu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Robu</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Salaru</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vajpayee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aye</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brega</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coad</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ivelja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilding</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hutchison</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cheney</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>150</volume>
            <issue>5</issue>
            <fpage>393</fpage>
            <page-range>393-405</page-range>
            <pub-id pub-id-type="pmid">30052721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <article-title>BONE MARROW, THYMUS AND BLOOD: CHANGES ACROSS THE LIFESPAN.</article-title>
            <source>Aging health</source>
            <year>2009</year>
            <month>Jun</month>
            <day>01</day>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>385</fpage>
            <page-range>385-393</page-range>
            <pub-id pub-id-type="pmid">20072723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Gatter</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>The bone marrow trephine biopsy: a review of normal histology.</article-title>
            <source>Histopathology</source>
            <year>1993</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-22</page-range>
            <pub-id pub-id-type="pmid">8344653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brynes</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Naemi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reisian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhansali</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Differentiating benign from malignant bone marrow B-cell lymphoid aggregates: a statistical analysis of distinguishing features.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>139</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-40</page-range>
            <pub-id pub-id-type="pmid">25611106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyd</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Natkunam</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Warnke</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.</article-title>
            <source>Appl Immunohistochem Mol Morphol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-31</page-range>
            <pub-id pub-id-type="pmid">22820658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkins</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Pitfalls in bone marrow pathology: avoiding errors in bone marrow trephine biopsy diagnosis.</article-title>
            <source>J Clin Pathol</source>
            <year>2011</year>
            <month>May</month>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>380</fpage>
            <page-range>380-6</page-range>
            <pub-id pub-id-type="pmid">21325142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Foucar</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Bone marrow involvement by hodgkin and non-hodgkin lymphomas.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>873</fpage>
            <page-range>873-902</page-range>
            <pub-id pub-id-type="pmid">19577173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>[Incidence and histologic patterns of bone marrow involvement of malignant lymphoma based on the World Health Organization classification: a single institution study].</article-title>
            <source>Korean J Lab Med</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>383</fpage>
            <page-range>383-7</page-range>
            <pub-id pub-id-type="pmid">18160826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sancheti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Somal</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Sali</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dora</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Gulia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Divetia</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Challenges Encountered and Pattern-Based Analysis of Bone Marrow Biopsy in Lymphomas: An Institutional Experience.</article-title>
            <source>J Lab Physicians</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-77</page-range>
            <pub-id pub-id-type="pmid">37064982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pardanani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.</article-title>
            <source>Am J Hematol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>508</fpage>
            <page-range>508-525</page-range>
            <pub-id pub-id-type="pmid">33524167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jayarangaiah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Theetha Kariyanna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Bone Metastasis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">29939688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goasguen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Brunning</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Vallesp&#x000ed;</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Renault</surname>
                <given-names>A</given-names>
              </name>
              <collab>International Working Group on Morphology of MDS IWGM-MDS</collab>
            </person-group>
            <article-title>Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia.</article-title>
            <source>Leuk Res</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>45</volume>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">27107657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Advances in molecular evaluation of myeloproliferative neoplasms.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2023</year>
            <month>May</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-194</page-range>
            <pub-id pub-id-type="pmid">37087305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kvasnicka</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Facchetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>van der Walt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orazi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>European consensus on grading bone marrow fibrosis and assessment of cellularity.</article-title>
            <source>Haematologica</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>90</volume>
            <issue>8</issue>
            <fpage>1128</fpage>
            <page-range>1128-32</page-range>
            <pub-id pub-id-type="pmid">16079113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gajendra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sachdev</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Multiple Myeloma: An Unusual Cause of Extensive Bone Marrow Necrosis.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>XL01</fpage>
            <page-range>XL01-XL02</page-range>
            <pub-id pub-id-type="pmid">27504393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deucher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wool</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>How I investigate bone marrow necrosis.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>585</fpage>
            <page-range>585-592</page-range>
            <pub-id pub-id-type="pmid">31424633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duncavage</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bagg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>DiNardo</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Godley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Iacobucci</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jaiswal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malcovati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vannucchi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Arcila</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bejar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Branford</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Cargo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Falini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Garcia-Manero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haferlach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hellstr&#x000f6;m-Lindberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Klco</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Komrokji</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee-Cheun Loh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loghavi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mullighan</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Papaemmanuil</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Savona</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Skoda</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Sol&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Genomic profiling for clinical decision making in&#x000a0;myeloid neoplasms and acute leukemia.</article-title>
            <source>Blood</source>
            <year>2022</year>
            <month>Nov</month>
            <day>24</day>
            <volume>140</volume>
            <issue>21</issue>
            <fpage>2228</fpage>
            <page-range>2228-2247</page-range>
            <pub-id pub-id-type="pmid">36130297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145905.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Orazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Kvasnicka</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bagg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Branford</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bueso-Ramos</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dal Cin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>DiNardo</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Dombret</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Duncavage</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Estey</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Facchetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Foucar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gangat</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gianelli</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Godley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>G&#x000f6;kbuget</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gotlib</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hellstr&#x000f6;m-Lindberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jabbour</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kiladjian</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Le Beau</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>L&#x000f6;wenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Macintyre</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Malcovati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mullighan</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Niemeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Odenike</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orfao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Papaemmanuil</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Passamonti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Porkka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Radich</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rozman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rudelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savona</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Schiffer</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schmitt-Graeff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shimamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sierra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tien</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Tzankov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vannucchi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Wierzbowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</article-title>
            <source>Blood</source>
            <year>2022</year>
            <month>Sep</month>
            <day>15</day>
            <volume>140</volume>
            <issue>11</issue>
            <fpage>1200</fpage>
            <page-range>1200-1228</page-range>
            <pub-id pub-id-type="pmid">35767897</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
